Nurix Therapeutics公布了其药物在二线治疗慢性淋巴细胞白血病患者中的最新数据。这些患者先前接受过布鲁顿酪氨酸激酶抑制剂治疗，但未接触过BCL2抑制剂。结果显示，客观缓解率达到了92.9%，展现了显著的临床活性。
Nurix Therapeutics公布了其药物在二线治疗慢性淋巴细胞白血病患者中的最新数据。这些患者先前接受过布鲁顿酪氨酸激酶抑制剂治疗，但未接触过BCL2抑制剂。结果显示，客观缓解率达到了92.9%，展现了显著的临床活性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.